Burden of Proof for Tolvaptan in ADPKD

Clinical Journal of the American Society of Nephrology - United States
doi 10.2215/cjn.00190118
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Society of Nephrology (ASN)

Related search

Puk16 - Cost-Effectiveness of Tolvaptan in Canadian Patients With Autosomal Polycystic Kidney Disease: An Adaptation of the Adpkd Outcomes Model

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

2. Burden of Proof and Presumptions

2015English

On the Optimal Burden of Proof

2012English

The Burden of Proof in Philosophical Persuasion Dialogue

Argumentation
LinguisticsPhilosophyLanguage
2017English

Idiosyncratic Hepatic Toxicity in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Patient in Combined Treatment With Tolvaptan and Amoxicillin/Clavulanic Acid: A Case Report

BMC Nephrology
Nephrology
2019English

Burden of Proof—When Is Kidney Disease Attributable to Diabetes?

Clinical Journal of the American Society of Nephrology
EpidemiologyNephrologyCritical CareTransplantationIntensive Care Medicine
2017English

Applying the Burden of Proof and Creating Connections to Communities

Constitutional Forum / Forum constitutionnel
2012English

Targeting Cyst Initiation in ADPKD

Journal of the American Society of Nephrology : JASN
MedicineNephrology
2008English

The Effect of Rebuttable Presumptions of Law Upon the Burden of Proof

University of Pennsylvania Law Review and American Law Register
1920English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy